The company’s patented PLX cells release therapeutic proteins in response to a host of local and systemic inflammatory diseases.
PLX cells are grown using the company’s proprietary 3D micro-environmental technology which requires no tissue matching prior to administration.
The company said Pluristem’s pre-clinical animal models have evaluated that the PLX cells are potentially effective in nerve pain and muscle damage, when administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically.
Hebrew University Medical Center Sharett Institute of Oncology at Hadassah Biotechnology and Radiobiology Laboratory head and investigator Raphael Gorodetsky said the higher survival rate of the PLX treated animals, compared to the control group, is accompanied with better hematological profile, as reflected by the increase of all the cell lines of the hematopoietic system and in the blood hemoglobin levels.
Pluristem chairman and CEO Zami Aberman said Stockpiled PLX cells can be administered acutely and as a bridging therapy to protect the bone marrow.